Estrogens and atherosclerosis: Phytoestrogens and selective estrogen receptor modulators

Current Opinion in Lipidology

Volumn 9, Issue 5, 1998, Pages 457-463

  St Clair, Richard W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTCHROMAN; DAIDZEIN; ESTROGEN; ESTROGEN RECEPTOR; GENISTEIN; ISOFLAVONE; LIPOPROTEIN; PHYTOESTROGEN; RALOXIFENE; TAMOXIFEN;

ARTERY WALL; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CLINICAL TRIAL; DRUG DESIGN; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SOYBEAN;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR SYSTEM; ESTROGENS; FEMALE; HUMANS; PLANT PROTEINS; RECEPTORS, ESTROGEN;

ANIMALIA; GLYCINE MAX;

EID: 0031732046     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199810000-00010     Document Type: Review

References (101)

1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes. A 26-year follow-up of the Framingham population. Am Heart J 1986; 111:383-390.
2. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis-prevailing assumptions and outstanding questions. Am Heart J 1987; 114:1467-1503.
3. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996; 87:S36-S43.
4. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20:47-63.
5. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991; 265:1861-1867.
6. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-1775. In a large prospective case control study of women taking postmenopausal hormone therapy (The Nurses=Health Study), deaths caused by coronary heart disease and stroke were reduced relative to non users (relative risk 0.47 and 0.68, respectively), as was total mortality (0.63). After 10 years of hormone therapy the benefits for coronary heart disease were retained while the benefit for total mortality was lost because of an increase in breast cancer.
7. Craig VJ. Studies on the estrogen receptor in breast cancer. Twenty years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995; 36:267-285.
8. Love RR, Mazess RB, Barden HS, Epstein HS, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852-856.
9. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Nat Cancer Inst 1994; 86:1534-1539.
10. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994; 14:1586-1593.
11. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80:3191-3195.
12. Gylling H, Mantyla E, Miettinen TA. Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis. Atherosclerosis 1992; 96:245-247.
13. Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nature Med 1995; 1:1067-1073.
14. Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 1997; 95:1542-1548.
15. Williams JK, Wagner JD, Li Z, Golden DL, Adams MR. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol 1997; 17:403-408.
16. Holm P, Shalmi M, Korsgaard N, Guldhammer B, Skouby SO, Slender S. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscler Thromb Vasc Biol 1997; 17:2264-2272.
17. Penotti M, Sironi L, Miglierina L, Farina M, Barletta L, Gabrielli L, Vignali M. The effect of tamoxifen and transdermal 17β-estradiol on cerebral arterial vessels: a randomized controlled study. Am J Obstet Gynecol 1998; 178:801-805. Cerebral artery reactivity was measured in postmenopausal women taking oral tamoxifen, transdermal estradiol, or no treatment. While estradiol had a positive effect on in-vivo vascular reactivity, tamoxifen was without effect.
18. Williams JK, Honoré EK, Adams MR. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates. Circulation 1997; 96:1970-1975. Quantitative angiography was used to measure coronary artery dilator response to intracoronary infusion of acetylcholine in atherosclerotic cynomolgus monkeys. Whereas coronary arteries from animals treated with conjugated equine estrogen dilated in response to acetylcholine, tamoxifen-treated animals constricted. Thus, tamoxifen unlike other estrogens does not promote vasodilation.
19. Love RR, Camerom L, Connell BL, Leventhal H. Sympyoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151:1842-1847.
20. Kurt RN, Borthwick NM. Clomiphene and tamoxifen action in the rat uterus. J Endocrinol 1980; 85:519-524.
21. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990; 35:235-238.
22. Fornander T, Rutqvist IE, Sjoberg HE, Blomqvist L, Mattson A, Glas V. V. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990; 8:1019-1024.
23. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 1997; 82:3425-3429.
24. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-1647.
25. Black LJ, Sato M, Rowley ER, Magee DE, Bekele KA, Williams DC, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63-69.
26. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998; 279:1445-1451.
27. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis 1996; 126:65-75.
28. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB 1996; 10:905-912.
29. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997; 96:1964-1969. The effect of raloxifene on atherosclerosis was studied in cholesterol-fed rabbits. Raloxifene reduced atherosclerosis in one segment of the aorta by one-third, compared with a two-thirds reduction with 17-β estradiol. Thus, raloxifene has only a weak effect on atherosclerosis development at the concentration used.
30. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83:721-726. The effect of raloxifene and conjugated equine estrogen on experimental atherosclerosis was studied in 117 ovariectomized female cynomolgus monkeys. There was no effect of two doses of raloxifene on coronary artery atherosclerosis, while conjugated equine estrogen reduced atherosclerosis by 70%. This suggests that even though raloxifene reduces plasma cholesterol concentrations, it does not possess the direct protective effects of estrogen on the arterial wall.
31. Farnsworth NR, Bingel AS, Cordell GA, Crane FA, Fong HHS. Potential value of plants as sources of new antifertility agents II. J Pharm Sci 1975; 64:717-754.
32. Murkies AL, Wilcox G, Davis SR. Clinical review 92, phytoestrogens. J Clin Endocrinol Metab 1998; 83:297-303.
33. Bingham SA, Atkinson C, Liggins J, Bluck L, Coward A. Phyto-oestrogens: where are we now? Br J Nutr 1998; 79:393-406. An excellent up-to-date review of the effects of phytoestrogens and their potential for benefits to human health and disease.
34. Markiewicz L, Garey J, Adiercreutz H, Gurpide E. In vitro bioassays of nonsteroidal phytoestrogens. J Steroid Biochem Molec Biol 1993; 45:399-405.
35. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat 1997; 46: 169-179.
36. Clarkson TB, Anthony MS, Williams JK, Honoré EK, Cline JM. The potential of soybean phytoestrogens for postmenopausal hormone replacement therapy. Proc Soc Exp Biol Med 1998; 217:365-368.
37. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997; 29:95-120.
38. Adlercreutz H. Western diet and western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Invest 1990; 50 (Suppl.): 201:3-23.
39. Huff MW, Roberts DCK, Carroll KK. Long-term effects of semipurified diets containing casein or soy protein isolate on atherosclerosis and plasma lipoproteins in rabbits. Atherosclerosis 1982; 41:327-336.
40. Carroll KK. Hypercholesterolemia and atherosclerosis: effects of dietary protein. Fed Proc 1982; 41:2792-2796.
41. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. New Engl J Med 1995; 333:276-282.
42. Carroll KK. Review of clinical studies on cholesterol lowering response to soy protein. J Am Diet Assoc 1991; 91:820-827.
43. Chait A, Brunzell JD, Denke MA, Eisenberg D, Ernst ND, Franklin FA, et al. Rationale of the Diet-Heart Statement of the American Heart Association Report of the Nutrition Committee. Circulation 1993; 88:3008-3029.
44. Porter SM. Overview of proposed mechanism for the hypocholesterolemic effect of soy. J Nutr 1995; 125:6063-6113.
45. Anthony MS, Clarkson TB, Hughes CL, Morgan TM, Burke GL. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr 1996; 126:43-50.
46. Anthony MS, Clarkson TB, Bullock BC, Wagner JD. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol 1997; 17:2524-2531. This is the first published study to evaluate the effect of soy protein and soy phytoestrogens on experimental atherosclerosis. Male cynomolgus monkeys consuming diets containing soy protein had lower plasma cholesterol concentrations and less coronary artery atherosclerosis than did animals consuming the same soy diet in which the phytoestrogens had been extracted from the soy protein with alcohol. This suggests that the phytoestrogens were partly responsible for these effects.
47. Sugano M, Koba K. Dietary protein and lipid metabolism: a multifunctional effect [review]. Ann NY Acad Sci 1993; 676:215-222.
48. Kirk EA, Sutherland P, Wang SA, Chait A, LeBoeuf RC. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr 1998; 128:954-959.
49. Sirtori CR, Gianazza E, Manzoni C, Lovati MR, Murphy PA. Role of isoflavones in the cholesterol reduction by soy proteins in the clinic. Am J Clin Nutr 1997; 65:166-167.
50. Tovar-Palacio C, Potter SM, Hafermann JC, Shay NF. Intake of soy protein and soy protein extracts influences lipid metabolism and hepatic gene expression in gerbils. J Nutr 1998; 128:839-842.
51. Balmir F, Staack R, Jeffery E, Jimenez MDB, Wang L, Potter SM. An extract of soy flour influences serum cholesterol and thyroid hormones in rats and hamsters. J Nutr 1996; 126:3046-3053.
52. Nestel PJ, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesarotf P, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997; 17:3392-3398. Postmenopausal women were given tablets containing 80 mg/day of extracted soy isoflavones for 5 weeks in a placebo-controlled crossover design. There was no effect of isoflavones on plasma lipoproteins, but isoflavone treatment enhanced vasodilatory capacity in response to acetylcholine.
53. Hodgson JM, Puddey IB, Beilin LJ, Mori TA. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. J Nutr 1998; 128:728-732. The addition of 52 mg/day of isoflavones to the diet of men and postmenopausal women in a placebo-controlled trial did not alter plasma lipoprotein concentrations in individuals with average serum cholesterol concentrations.
54. Wahl PW, Walden CE, Knapp RH, Wallace R, Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983; 308:862-867.
55. Honoré EK, Williams JK, Anthony MS, Clarkson TB. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril 1997; 67:148-154.
56. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81:1680-1687.
57. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994; 121:936-941.
58. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Molec Biol 1998; 64:187-191.
59. Guetta V, Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996; 93:1928-1937.
60. Sulistiyani, Adelman SJ, Chandrasekaran A, Jayo J, St Clair RW. Effect of 17 α-dihydroequilin sulfate, a conjugated equine estrogen, and ethinyl estradiol on atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15:837-846.
61. Elhage R, Bayard F, Richard V, Holvoet P, Duverger N, Fievet C, Arnal JF. Prevention of fatty streak formation of 17 beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation 1997; 96:3048-3052.
62. Elhage R, Arnal JF, Pieraggi M-T, Duverger N, Fievet C, Faye JC, Bayard F. 17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1997, 17:2679-2684.
63. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Arteriosclerosis 1990; 10:1051-1057.
64. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:217-221. Conjugated equine estrogen given to cynomolgus monkeys fed an atherogenic diet for 30 months reduced coronary artery atherosclerosis by 72%. Inclusion of the progestin medroxyprogesterone acetate with the conjugated equine estrogen for the duration of the experiment completely prevented the protective effects of conjugated equine estrogen. This could have serious implications for the long-term benefits on coronary heart disease of current formulations for hormone replacement therapy which use medroxyprogesterone acetate.
65. Akishita M, Ouchi Y, Miyoshi H, Orimo A, Kozaki K, Eto M, et al. Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Atherosclerosis 1996; 125:27-38.
66. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17 beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98:36-42.
67. Arnal JF, Clamens S, Pechet C, Negresalvayre A, Allera C, Girolami JP, et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting Superoxide anion production. Proc Natl Acad Sci USA 1996; 93:4108-4113.
68. Mikkola T, Ranta V, Orpana A, Ylikorkala O, Viinikka L. Effect of physiological concentrations of estradiol on PGI (2) and NO in endothelial cells. Maturitas 1996; 25:141-147.
69. Holm P, Stender S, Andersen HO, Hansen BF, Nordestgaard BG. Antiatherogenic effect of estrogen abolished by balloon catheter injury in cholesterol-clamped rabbits. Arterioscler Thromb Vasc Biol 1997; 17:1504-1511.
70. Holm P, Korsgaard N, Shalmi M, Andersen HL, Hougaard P, Skouby SO, Slender S. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest 1997; 100:821-828.
71. Koh KK, Bui MN, Mincemoyer R, Cannon RO. Effects of hormone therapy on inflammatory cell adhesion molecules in postmenopausal healthy women. Am J Cardiol 1997; 80:1505-1507.
72. Okada M, Suzuki A, Mizuno K, Asada Y, Ino Y, Kuwayama T, et al. Effects of 17 beta-estradiol and progesterone on migration of human monocytic THP-1 cells stimulated by minimally oxidized low-density lipoprotein in vitro. Cardiovasc Res 1997; 34:529-535.
73. Tomita T, Sawamura F, Uetsuka R, Chiba T, Miura S, Ikeda M, Tomita I. Inhibition of cholesteryl ester accumulation by 17 beta-estradiol in macrophages through activation of neutral cholesterol esterase. Lipid Metab 1996; 1300:210-218.
74. St Clair RW. Effects of estrogens on macrophage foam cells: a potential target for the protective effects of estrogens on atherosclerosis. Curr Opin Lipidol 1997; 8:281-286.
75. Chao TC, Phuangsab A, Vanalten PJ, Walter RJ. Steroid sex hormones and macrophage function: regulation of chemiluminescence and phagocytosis. Am J Reprod Immunol 1996; 35:106-113.
76. Frazier-Jessen MR, Kovacs EJ. Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol 1995; 154:1838-1845.
77. Frazier-Jessen MR, Mott FJ, Witte PL, Kovacs EJ. Estrogen suppression of connective tissue deposition in a murine model of peritoneal adhesion formation. J Immunol 1996; 156:3036-3042.
78. Haarbo J, Nielsen LB, Stender S, Christiansen C. Aortic permeability to LDL during estrogen therapy-a study in normocholesterolemic rabbits. Arterioscler Thromb 1994; 14:243-247.
79. Wagner JD, Clarkson TB, St Glair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces LDL accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991; 88:1995-2002.
80. Wagner JD, St Clair RW, Schwenke DS, Shively CA, Adams MR, Clarkson TB. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys. Effects of estrogen and progesterone replacement therapy. Arterioscler Thromb 1992; 12:717-726.
81. Alexandersen P, Haarbo J, Sandholdt I, Shalmi M, Lawaetz H, Christiansen C. Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol. A secondary prevention study of aortic atherosclerosis in ovariectomized cholestero-fed rabbits. Arterioscler Thromb Vasc Biol 1998; 18:902-907. Norethindrone acetate is a 19-nortestosterone derivative that reduces the uterotropic effects of estrogens and is used in combination with estrogens for hormone replacement therapy. Some progestins used for this purpose have been reported to reduce the beneficial effects of estrogen on atherosclerosis; see [64]. When norethindrone acetate was tested in this study in ovariectomized cholesterol-fed rabbits it was found to enhance the protective effects of estradiol.
82. Rhee CY, Spaet TH, Stemmerman MB, Lajam F, Shiang HH. Estrogen suppression of surgically induced vascular intimal hyperplasia in rabbits. J Lab Clin Med 1977; 90:77-84.
83. Jacobsson J, Cheng L, Lyke K, Kuwahara M, Kagan E, Ramwell P, Foegh ML. Effect of estradiol on accelerated atherosclerosis in rabbit hetertropic aortic allografts. J Heart Lung Transpl 1992; 11:1188-1193.
84. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 1996; 148:969-976.
85. Morey AK, Pedram A, Razandi M, Prins BA, Hu RM, Biesiada E, Levin ER. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 1997; 138:3330-3339.
86. Wang W, Smith R III, Burghardt R, Safe SH. 17 beta-estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. Mol Cell Endocrinol 1997; 133:49-62.
87. Lou HL, Zhao Y, Delafontaine P, Kodama T, Katz N, Ramwell PW, Foegh ML. Estrogen effects on insulin-like growth factor-I (IGF-I)-induced cell proliferation and IGF-I expression in native and allograft vessels. Circulation 1997; 96:927-933.
88. 2+ release induced by thromboxane A(2) in porcine coronary artery. Circulation 1995; 91:2619-2626.
89. Bellinger DA, Williams JK, Adams MR, Honoré EK, Bender DE. Oral contraceptives and hormone replacement therapy do not increase the incidence of arterial thrombosis in a nonhuman primate model. Arterioscler Thromb Vasc Biol 1998; 18:92-99.
90. Hulley S, Grady D, Bush T, Furberg C, Henrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-613. After 4.1 years of treatment with conjugated equine estrogens plus medroxyprogesterone acetate in postmenopausal women with coronary heart disease, there was no reduction in the overall rates of coronary heart disease events. Since this is in contrast to other studies with estrogen alone or in combination with other progestins, one interpretation that is consistent with studies in monkeys [64] is the specific progestin (medroxyprogesterone) used in this study prevented the protective effect of estrogens.
91. Inoue S, Hoshino S, Miyoshi H, Akishita M, Hosoi T, Orimo H, Ouchi Y. Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle cells. Biochem Biophys Res Commun 1996; 219:766-772.
92. Campisi D, Cutolo M, Carruba G, Locasto M, Comito L, Granata OM, et al. Evidence for soluble and nuclear site I binding of estrogens in human aorta. Atherosclerosis 1993; 103:267-277.
93. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994; 89: 1501-1510.
94. Gulshan S, McCruden AB, Stimson WH. Oestrogen receptors in macrophages. Scand J Immunol 1990; 31:691-697.
95. Vickers AEM, Lucier GW. Estrogen receptor levels and occupancy in hepatic sinusoidal endothelial and Kuptfer cells are enhanced by initiation with diethylnitrosamine and promotion with 17 alpha-ethinylestradiol in rats. Carcinogenesis 1996; 17:1235-1242.
96. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta-gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997; 99:2429-2437.
97. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR, Lubahn DB, et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nature Med 1997; 3:545-548.
98. Farhat MY, Abi-Younes S, Ramwell PW. Non-genomic effects of estrogen and the vessel wall. Biochem Pharmacol 1996; 51:571-576.
99. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J 1996; 10:615-624.
100. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ER alpha) and estrogen receptor-beta (ER beta) messenger ribonucleic acid in the wild-type and ER alpha-knockout mouse. Endocrinology 1997; 138:4613-4621.
101. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138:863-870.